AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review

Berberine repurposing for clinical translation: multi-target synergy, combinatorial approaches, and self-assembled delivery strategies

Qizhe Maa, Shuo Zhanga,b( ), Yun Chaia,c, Xi Maoa, Dingqiao Xua, Ruijia Fua, Yuping Tanga,c( )
Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine, Xianyang 712046, China
State Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China
Show Author Information

Abstract

Berberine (BBR) is an active component in traditional Chinese medicine with a long history of clinical application. In recent years, its remarkable multi-target pharmacological properties have attracted extensive attention in modern biomedical research. Traditionally known for its antibacterial and anti-inflammatory effects, BBR is now widely used in the treatment of metabolic disorders, cardiovascular diseases, cancer, and neurological diseases. However, due to its low oral bioavailability, clinical translation has been severely limited. Moreover, BBR mainly accumulates in the intestine, resulting in a low systemic exposure level, which leads to a gap between the effective concentration in the preclinical stage and the actual achievable plasma concentration level. This article focuses on the bottleneck issue of BBR’s bioavailability, providing a comprehensive and systematic summary from aspects such as multi-target action mechanisms, synergistic combination strategies, carrier-free self-assembling formulation methods, as well as existing research evidence, drug transformation prospects, safety issues, and drug interactions. It clarifies the existing opportunities and challenges of BBR, aiming to promote the further development of BBR therapy and provide new ideas for its clinical translation.

References

【1】
【1】
 
 
Chinese Journal of Natural Medicines
Pages 1444-1458

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Ma Q, Zhang S, Chai Y, et al. Berberine repurposing for clinical translation: multi-target synergy, combinatorial approaches, and self-assembled delivery strategies. Chinese Journal of Natural Medicines, 2026, 24(12): 1444-1458. https://doi.org/10.1016/S1875-5364(26)61232-0

8

Views

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 17 August 2026
Revised: 29 September 2026
Accepted: 03 October 2026
Published: 20 December 2026
© 2026, China Pharmaceutical University.